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PHARMACOECONOMIC IMPACT OF UPFRONT USE PLERIXAFOR FOR AU-
TOLOGOUS STEM CELL MOBILIZATION IN MULTIPLE MYELOMA PA-
TIENTS
Isola, L.1, Banoff, K.2, Kim, S.S.3 1TheMount SinaiMedical Center, New
York, NY; 2The Mount Sinai Medical Center, New York, NY; 3The
Mount Sinai Medical Center, New York, NY
Stem cell mobilization with granulocyte-colony-stimulating fac-
tor (G-CSF) is associated with about 25% of unsuccessful mobiliza-
tion. Plerixafor was granted FDA approval based on improved rate of
successful mobilization as an upfront mobilizing agent. However,
because of its cost, it is often reserved for patients who failed previous
standard mobilization.
This retrospective study, performed between January 2008 and
April 2011, included 50 adult patients with multiple myeloma
(MM) who underwent ASCT. Twenty-five patients received plerix-
afor, in combination with G-CSF, and 25 patients received G-CSF
alone as an upfront mobilization therapy. In April 2010, a practice
change was instituted to delay initiation of G-CSF from day 0 to
day +5 following ASCT. Simultaneously, plerixafor was used, in
combination withG-CSF, as an upfrontmobilization therapy for au-
tologous stem cell mobilization inMM patients. The primary objec-
tive of this study was to assess pharmacoeconomic impact of using
plerixafor as an upfront mobilization therapy in patients with MM.
Compared with the control, plerixafor mobilizations yielded higher
CD34+ cell content [mean (x106 CD34+ cells/kg), 16.1 vs. 8.4; p 5
0.0007], higher number of CD34+cells infused [mean (x106
CD34+ cells/kg), 7.6 vs. 4.4; p 5 0.0017], required fewer number
of G-CSF doses for both stem cell collection (mean, 5.9 vs. 7.1;
p 5 0.0001) and for neutrophil recovery (mean, 8 vs. 11.8;
p\0.0001), and required fewer number of apheresis (mean, 1.9 vs.
3.1; p 5 0.0001). The plerixafor group had a longer time to neutro-
phil engraftment by one day; however, this did not translated to lon-
ger days of hospitalization post-ASCT in the plerixafor group (mean,
15.2 days vs. 14.1 days; p 5 NS). In the plerixafor group, the mean
number of plerixafor doses per patient was 1.8, and $9,082 per pa-
tient. The overall cost of medications was lower in the plerixafor
group (mean, $18,538 vs. $22,442; p 5 0.014); however the plerixa-
for group had similar cost for blood products per patient (mean,
$2,029 vs. $2,332; p 5 NS), overall cost of hospitalization (mean,
$57,424 vs. $61,474; p 5NS), and combined cost of hospitalization
and apheresis per patient (mean, $58,315 vs. $62,949; p 5 NS).
This data suggests that using plerixafor for upfront autologous
stem cell mobilization in patients with MM significantly improves
success rate of mobilization, decreases the number of apheresis
sessions, and does not have a substantial pharmacoeconomic
impact.93
IMMUNOGENICITY OF POLYSACCHARIDE PNEUMOCOCCAL VACCINA-
TION IN AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
Lukenbill, J., Mossad, S., Butler, R., Sobecks, R., Andresen, S.,
Copelan, E., Dean, R., Duong, H., Kalaycio, M., Hill, B., Pohlman, B.,
Sweetenham, J., Bolwell, B. Taussig Cancer Center, Cleveland, OH
Background: Patients undergoing autologous hematopoietic cell
transplant (AHCT) are susceptible to pneumococcal infections.
The CDC recommends pneumococcal vaccination of immunocom-
promised patients including AHCT recipients. We prospectively
collected pneumococcal IgG titers in AHCT patients from prior
to transplant until after their one year post-transplant polysaccharide
pneumococcal vaccination (PSV23), with the goal of determining the
immunological response of vaccination.
Methods: From June 2009 through March 2010, 50 participants
with Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, or multiple
myeloma scheduled for AHCT consented to have their serum col-
lected prior to transplant (Titer 1), 3-7 days following ASCT (Titer
2), 1 year later at the time of vaccination (Titer 3), and at 4-6 wks af-
ter vaccination (Titer 4). Adequate immunological response was de-
fined as a $ 4-fold increase in titer or a titer of . 1.3 mg/dL
following vaccination. Of the 50 patients enrolled, 10 expired, 2
had disease progression, 1 developed co-morbidity preventing trans-plant, and 27 resumed care with their local oncologists within 1 year
following ASCT (before Titer 3). Data were collected through the
second titer for 35 participants, and all 4 titers for 10 participants.
Results: No significant change in titer was demonstrated immedi-
ately following AHCT (Titer 1 to 2) or at 1 year follow-up (Titer
2 to 3). Furthermore, adequate antibody response after vaccination
(Titer 3 to 4) occurred for only 3 of the 23 of the serotypes: 4,
12F, and 15B (p5 0.05).When compared to 50 healthy historic con-
trols who did not undergo ASCT, there was a significantly lower re-
sponse of the 5 serotypes compared (4, 8, 12F, 14, 19F) in our ASCT
patients (p\ 0.0001).
Conclusion:We conclude that there is minimal measurable immu-
nological response to the PSV23 vaccination following AHCT. Cur-
rent guidelines recommend the 7-serotype (4, 6B, 9V, 14, 18C, 19F,
and 23F) pneumococcal conjugate vaccine starting at 3-6months fol-
lowing transplantation, followed by 2 boosters 1-2 months apart,
with the option of PSV23 vaccination at 1-year post-transplant.
Our study highlights the urgency of further investigation into opti-
mal vaccination strategies in AHCT recipients.94
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AlloHCT can result in significant financial impact on patients and
their caregivers. Patient out-of-pocket costs associated with HCT
are not well known.We conducted a pilot study to determine the fea-
sibility of measuring out-of-pocket costs during HCT. Adult recip-
ients or parents/guardians of pediatric recipients of allo HCT were
eligible to participate if they were within 2 years of diagnosis of their
underlying disease and had sufficient English proficiency. Recipients
were required to have a caregiver who was a member of their house-
hold. Prior to HCT, participants completed a baseline survey re-
garding household income, resources and insurance coverage.
Subsequently, they maintained a diary to track daily out-of-pocket
costs for the first 3 months after HCT. In the event of patient death,
the caregiver could continue participating in the study. The paper-
based diary was developed by study investigators and was designed
to capture expenses related to meals, lodging, uncovered medical
costs, transportation and other expenses. Participants mailed diaries
to the CIBMTR every 2 weeks and were given a gift card for each
submitted diary. Telephone interviews were conducted to followup
onmissing/incomplete diaries.Within 4 weeks of completing the di-
ary phase, a telephone interview was conducted to evaluate the diary.
Patient, disease and HCT information was obtained from the
CIBMTR database. Three sites enrolled 10 patients each; 25 com-
pleted the baseline survey, 15 completed all diaries over 3 months
and 18 evaluated the diary at the end of 3 months. On average it
took 22 minutes/day to complete the diary. Reasons for dropout
were patient death (N 5 4), burden of completing diary (N 5 2)
and other (N 5 4). Participant baseline demographics and out-of-
pocket costs are described in the table. Pre HCT, 20/25 (80%)
expected HCT would have a great/moderate impact on household
income, and only 8 (32%) were very confident/confident that they
would be able to meet their financial obligations. 15/18 (83%) par-
ticipants who completed study evaluation found the diary easy to
use and 12 (67%) felt phone reminders were helpful. 13 (72%) felt
very/somewhat comfortable answering income questions and 16
(89%) felt very/somewhat comfortable answering questions about
expenses. Our study shows feasibility of using a paper-based instru-
ment to capture out-of-pocket costs related to HCT. Qualitative
data obtained with evaluations will be used to further refine the
instrument.
S238 Oral PresentationsTable. Patient demographics and out of pocket costs for first
3 months after allogeneic HCTPatient characteristics N 5 25
Median patient age (range) 44 (24-71) years
Non-Hispanic White race 24 (96%)
Residence >50 miles from HCT center 12 (48%)
Needed temporary move to HCT center 12 (48%)
Median annual pre-tax income at study
enrollment (range)$65,000 (18,500-150,000)Household income reduced due to illness 20 (80%)
Diagnosis
Acute leukemia/MDS 22 (88%)
Other 3 (12%)Donor type
Related 10 (40%)
Unrelated/UCB 15 (60%)Conditioning intensity
Myeloablative 12 (48%)
Non-myeloablative/RIC 13 (52%)Out-of-pocket costs N 5 15
Median costs (inter-quartile range)
Temporary lodging $2,865 (1,126-3,972)
Transportation $220 (162-576)
Food $701 (301-1,172)
Uncovered medical expenses $507 (250-1,157)
Other $180 (38-1,222)Median miles driven per day (range) 24 (2-96)95
RETROSPECTIVE STUDY OF ARRHYTHMIAS DURING HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Stillwell, E.E.1, Calloway, J.3, Glew, T.3, Wessler, J.D.2, Rebdollo, B.J.4,
Steingart, R.M.1, Jakubowski, A.A.1, Schaffer, W.L.1 1Memorial
Sloan-Kettering Cancer Center, New York, NY; 2Harvard Medical
School, Boston, MA; 3New York Presbyterian - Cornell Hospital, New
York, NY; 4Weill Medical College of Cornell, New York, NY
Arrhythmias during hematopoietic stem cell transplantation may
impact morbidity and mortality. Prior studies report 12-23% of
older patients experience transplant arrhythmias, though the impact
on mortality and overall survival is not clear. Results of a retrospec-
tive analysis of 1255 autologous or allogenic stem cell transplanta-
tions in 1178 patients, age 40 years and older, 43 of whom had
pre-existing arrhythmias, are reported. Cancer diagnoses were pre-
dominantly leukemia, lymphoma and multiple myeloma. Only
symptomatic arrhythmias and those requiring a change in medical
management were included.
Patients with pre-existing arrhythmias were more likely to experi-
ence transplant arrhythmias (38.6% vs 5.1%, p 5\0.0001), pre-
dominantly atrial fibrillation and atrial flutter. They were more
likely to be admitted to the ICU (22.7% vs 9.5%, p 5 0.009) and
had longer hospital stays (33.9 6 24.9 days vs 28.1 6 18.1 days, p
5 0.037). In-hospital death and death within one year of transplan-
tation were more frequent in patients with pre-existing arrhythmias
(22.7% vs 4.3%, p 5\0.0001 and 36.4% vs 16.3%, p 5 0.002, re-
spectively).
Transplant arrhythmias in patients with no prior history of ar-
rhythmias were also analyzed. These were predominantly atrial fi-
brillation and atrial flutter. Patients who experienced arrhythmias
were older, but did not have conventional risk factors for cardiac dis-
ease more frequently than those who did not experience arrhythmias.
Arrhythmias were more frequent with bone marrow transplantation
(BMT) compared to peripheral blood stem cell transplantation
(13.9% vs. 4.85%, p 5 0.033), though the numbers of patients un-
dergoing BMT was small, and with allogeneic transplantation com-
pared to autologous (7.98% vs. 3.57%, p 5 0.002). Arrhythmias
during transplantation were associated with poorer outcomes. Pa-
tients who experienced arrhythmias were more likely to be admitted
to the ICU (51.61% vs 7.22%, p 5\.001) and to have longer hos-
pital stays (40.986 24.86 vs 27.356 17.39, p5\.001). Both in-hos-
pital mortality and death within one year of transplantation were
higher (27.43% vs 3.05%, p\0.001 and 41.94% vs 14.9%,
p\0.001, respectively).Overall, transplant arrhythmias correlated with increasedmorbid-
ity and mortality. Though this study is limited by small numbers and
retrospective data, the cumulative evidence suggests prospective
studies and possibly more aggressive management of arrhythmias
during transplantation may be warranted.96
RISK FACTORS AND OUTCOMES IN PATIENTS WITH ATYPICAL MOLD IN-
FECTION (AMI) FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION (HCT): A CIBMTR ANALYSIS FROM THE INFECTION
AND IMMUNE RECONSTITUTION WORKING COMMITTEE
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After allogeneic HCT, 14 - 17% of patients die primarily due to
infections. The impact of AMI on transplant outcome and risk fac-
tors for AMI has not been well assessed in the current era of anti-
fungal agents. To assess this, the CIBMTR analyzed characteristics
and outcomes of patients receiving allogeneic HCT from 1995 -
2008. Cases (n 5 124) had a Zygomycetes [n 5 72 (58%)] or Fu-
sarium [n 5 52 (42%)] AMI between day 0 - 365 after HCT. A
control (ctl) cohort (n 5 11856) included all patients from the
same 66 centers as cases. HCT indication was malignancy in 106
(85%) cases and 9603 (81%) ctl. The median (range) follow-up
of cases and ctl is 61 (13 – 132) and 62 months (1 – 186), respec-
tively. Cases were older [41 yrs (1 – 68) vs 34 yrs (1 – 79); p 5
0.004] and more likely to have a KPS \90% at HCT [cases 5
50 (40%); ctl 5 3330 (28%); p 5 0.009]. Similar numbers of cases
occurred before and after May 2002 when voriconazole was FDA
approved [1995 – Apr 2002 5 60 (48%); May 2002 – 2008 5 64
(52%)]. Systemic antifungal prophylaxis (Table 1) was similar be-
tween cases and ctl (p 5 0.64). The median time from HCT
to AMI was 48 days (0 – 363) with most occurring between day
0 – 100 [day 0 – 30 5 49 (40%); day 31 – 60 5 18 (15%); day
61 – 100 5 22 (18%)]. AMI diagnosis significantly impacted 1-
year survival (OS) with a probability (95% CI) for cases of only
22% (15 – 29) compared to 65% (64 – 65) for ctl [p \0.001].
OS after the diagnosis of AMI was dismal at 52% (42 – 60) by
30 days following AMI and 27% (20 – 35) by day 100. In multivar-
iate analysis of OS, AMI increased the risk of death 6-fold
(p\0.0001) regardless of the site (Blood, GI, Respiratory, Other)
or the timing of infection. Compared to ctl, AMI beyond 100
days resulted in inferior survival vs AMI between day 0 - 30 [RR
of death 11.78 (7.76 – 17.87) vs 5.67 (4.14 – 7.77); p 5 0.006].
In multivariate analysis, time dependent factors occurring before
and which increase the risk of AMI include grade II – IV acute
GVHD [1.71 (1.13 – 2.58), p 5 0.01], chronic GVHD [2.40
(1.21 – 4.75), p 5 0.01], and prior Aspergillus infection [7.29
(3.70 – 13.38), p\0.001]. The only other significant factor for de-
veloping AMI was KPS \90% [1.92 (1.34 – 2.77), p 5 0.0004].
Year of HCT, co-morbid conditions, stem cell source, disease/dis-
ease status, age, donor/recipient CMV serostatus and conditioning
intensity were not significant. In conclusion, AMI occurs infre-
quently but appears similar in the current antifungal era and
remains associated with high morbidity.
Table. Antifungal Prophylaxis reported in Cases with AMI and
Controls
Antifungal Agent Cases [N(%)] Controls [N(%)]None 19 (15) 2000 (17)
Fluconazole 57 (46) 6264 (53)
Amphotericin 27 (22) 1782 (15)
Voriconazole 9 (7) 683 (6)
Echinocandin 1 (<1) 158 (1)
Other, including trials 11 (9) 969 (8)
